GlassScriptPhysician profile
Sandeep Kour
NPI 1083037915
$34,265.73
in general payments reported to CMS, 2019-2025
44 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $311 · 2021: $44.49 · 2022: $681 · 2023: $1,482 · 2024: $3,722 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $8,192 · Honoraria: $5,515 · Travel and Lodging: $2,753 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,465.00 |
| Food and Beverage | $8,191.62 |
| Honoraria | $5,515.00 |
| Travel and Lodging | $2,752.76 |
| Education | $101.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $18,821.37 | 2019-2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $8,583.34 | 2023-2025 | Yorvipath |
| Amgen INC. | $1,160.32 | 2020-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $1,046.69 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $783.55 | 2020-2025 | Mounjaro, Zepbound, Omvoh |
| Medtronic, INC. | $389.01 | 2022-2025 | Minimed 780g, Appose Ulc |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.08 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $339.52 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Astellas Pharma US INC | $262.42 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $244.31 | 2019-2024 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $243.20 | 2022-2025 | Entyvio |
| Alexion Pharmaceuticals, INC. | $211.02 | 2023-2025 | Strensiq |
| Qol Medical, LLC | $195.47 | 2024-2025 | Sucraid, Sucraid |
| Ibsa Pharma INC. | $172.47 | 2024-2025 | Tirosint, Licart, Flector |
| Asensus Surgical, INC. | $164.52 | 2022-2024 | Senhance |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $161.71 | 2023-2025 | Omnipod |
| Mannkind Corporation | $118.80 | 2022 | |
| Abbvie INC. | $115.39 | 2019-2025 | |
| Janssen Biotech, INC. | $104.88 | 2020-2025 | Tremfya, Simponi, Stelara |
| Radius Health, INC. | $89.14 | 2020-2025 | Tymlos |
| Ardelyx, INC. | $72.90 | 2022-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $65.66 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.06 | 2019-2023 | Xifaxan, Plenvu |
| Merck Sharp & Dohme LLC | $48.08 | 2020-2024 | Zinplava, Dificid |
| Kyowa Kirin, INC. | $38.22 | 2025 | |
| Abbott Laboratories | $37.19 | 2020-2023 | Freestyle Libre 3 |
| Braintree Laboratories, INC. | $34.50 | 2023-2024 | Sutab, Suflave |
| Tandem Diabetes Care, INC. | $31.90 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Exact Sciences Corporation | $28.81 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $27.08 | 2019 | |
| Dexcom, INC. | $20.91 | 2023 | Dexcom G6 Transmitter |
| Amryt Pharma Holdings LTD | $19.91 | 2023 | Mycapssa |
| Blueprint Medicines Corporation | $19.51 | 2024 | Ayvakit |
| Phathom Pharmaceuticals, INC. | $18.96 | 2025 | Voquezna |
| Biocon Biologics INC | $18.44 | 2025 | Yesintek |
| Biohaven Pharmaceutical Holding Company LTD. | $17.92 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.28 | 2023 | Adthyza |
| Cequr Corporation | $16.37 | 2023 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $15.48 | 2020 | |
| Ucb, INC. | $14.57 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.07 | 2019 | |
| Horizon Therapeutics Plc | $13.64 | 2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $13.49 | 2025 | |
| Arbor Pharmaceuticals, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Kour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.